Outlook Therapeutics (NASDAQ:OTLK) PT Lowered to $33.00

Outlook Therapeutics (NASDAQ:OTLK) had its price objective trimmed by Ascendiant Capital Markets from $35.00 to $33.00 in a report issued on Tuesday, Benzinga reports. The firm currently has a buy rating on the stock.

Several other research firms have also recently weighed in on OTLK. HC Wainwright reiterated a buy rating and set a $30.00 price objective on shares of Outlook Therapeutics in a research report on Thursday, August 15th. Chardan Capital reissued a buy rating and issued a $53.00 price objective on shares of Outlook Therapeutics in a report on Friday, August 16th. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has a consensus rating of Buy and an average target price of $48.20.

Outlook Therapeutics Stock Up 6.3 %

Shares of NASDAQ:OTLK opened at $7.82 on Tuesday. The stock has a market cap of $185.02 million, a PE ratio of -0.69 and a beta of 0.64. The business has a 50 day moving average of $7.66 and a 200-day moving average of $7.97. Outlook Therapeutics has a 12-month low of $4.00 and a 12-month high of $18.00.

Hedge Funds Weigh In On Outlook Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the company. AQR Capital Management LLC bought a new position in Outlook Therapeutics in the second quarter valued at approximately $75,000. Squarepoint Ops LLC acquired a new stake in shares of Outlook Therapeutics in the 2nd quarter valued at $232,000. Susquehanna Fundamental Investments LLC bought a new position in shares of Outlook Therapeutics in the 2nd quarter valued at $303,000. LVW Advisors LLC bought a new stake in shares of Outlook Therapeutics during the 2nd quarter worth $352,000. Finally, Rosalind Advisors Inc. bought a new stake in shares of Outlook Therapeutics during the 1st quarter worth $3,723,000. 11.20% of the stock is currently owned by institutional investors and hedge funds.

Outlook Therapeutics Company Profile

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.